[Federal Register Volume 76, Number 51 (Wednesday, March 16, 2011)]
[Notices]
[Pages 14417-14418]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-6124]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice of intent to grant exclusive license.

-----------------------------------------------------------------------

SUMMARY: Pursuant to 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), 
this will serve to notify the public that the National Institutes of 
Health, Department of Health and Human Services, is contemplating the 
grant of an exclusive patent license to intellectual property broker 
ICAP Ocean Tomo to promote the utilization by the public of the 
inventions described in the following U.S. patents: 7,122,624

[[Page 14418]]

entitled ``PH2 Receptor Ligands'' (HHS Ref. No. E-123-1999/0), and 
7,087,736 entitled ``Tyrosine DNA phosphodiesterases (TDP) and related 
polypeptides, nucleic acids, vectors, TDP producing host cells, 
antibodies and methods of use'' (HHS Ref. No. E-281-1999/0). The patent 
rights in this invention have been assigned to the United States of 
America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be for the use of the Licensed Patent Rights in 
developing biopharmaceutical products.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
March 31, 2011 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Mojdeh Bahar, J.D., Chief, Cancer 
Branch, Office of Technology Transfer, National Institutes of Health, 
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-2950; Facsimile: (301) 402-0220; E-mail: 
<a href="/cdn-cgi/l/email-protection#abc9cac3cad9c6ebc6cac2c785c5c2c385ccc4dd"><span class="__cf_email__" data-cfemail="9cfefdf4fdeef1dcf1fdf5f0b2f2f5f4b2fbf3ea">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: Prior to March 31, 2011, with NIH's explicit 
prior consent, ICAP will advertise the availability of the NIH 
technologies for licensing. Bidders may bid at anytime. Before any bid 
is accepted, NIH will review the commercial development plan (CDP) and 
assess the suitability of the bidder as a licensee.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within 
fifteen(15) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 9, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-6124 Filed 3-15-11; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>